Clinical Trial Update: Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 study investigating zanubrutinib combined with eltrombopag as second-line therapy in adults with immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN